Alligator Bioscience AB (ATORX) — Cash Flow-to-Debt Ratio
Alligator Bioscience AB (ATORX) has a Cash Flow-to-Debt Ratio of -0.25x as of December 2025, meaning its operating cash flow of Skr-26.00 Million could theoretically repay 0% of its total liabilities (Skr103.74 Million) in one year. See ATORX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Alligator Bioscience AB Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Alligator Bioscience AB across 13 annual periods. Also explore ATORX net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Alligator Bioscience AB (2011–2025)
Year-by-year debt coverage analysis for Alligator Bioscience AB. For market capitalisation and broader financial context, see ATORX stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.50x | Skr-155.99 Million | Skr103.74 Million | ▼ -66.3% |
| 2024 | -0.90x | Skr-212.43 Million | Skr234.93 Million | ▲ +49.1% |
| 2023 | -1.78x | Skr-189.28 Million | Skr106.59 Million | ▲ +17.1% |
| 2022 | -2.14x | Skr-172.61 Million | Skr80.53 Million | ▲ +14.1% |
| 2021 | -2.49x | Skr-127.03 Million | Skr50.93 Million | ▲ +35.2% |
| 2020 | -3.85x | Skr-141.35 Million | Skr36.69 Million | ▼ -13.3% |
| 2019 | -3.40x | Skr-178.96 Million | Skr52.63 Million | ▼ -30.1% |
| 2018 | -2.61x | Skr-104.11 Million | Skr39.85 Million | ▲ +34.2% |
| 2017 | -3.97x | Skr-99.63 Million | Skr25.08 Million | ▼ -159.8% |
| 2016 | -1.53x | Skr-37.61 Million | Skr24.59 Million | ▼ -114.4% |
| 2015 | 10.62x | Skr204.89 Million | Skr19.29 Million | ▲ +595.7% |
| 2014 | -2.14x | Skr-62.74 Million | Skr29.27 Million | ▲ +43.8% |
| 2011 | -3.82x | Skr-34.77 Million | Skr9.11 Million | — |